You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
宜明昂科-B(01541.HK)公佈IMM0306聯合來那度胺治療慢性淋巴瘤的積極臨牀試驗結果
格隆匯 11-18 08:06

格隆匯11月18日丨宜明昂科-B(01541.HK)發佈公吿,IMM0306與來那度胺聯用治療慢性淋巴瘤的Ib/IIa期臨牀試驗於2024年10月26日已合共招募27例可評估的患者(25例濾泡性淋巴瘤(FL)患者及兩例邊緣區淋巴瘤(MZL)患者)。下圖説明覆發性或難治性(R/R)FL患者截至2024年10月26日的療效數據:

截至2024年10月26日,於25例可評估的R/R FL患者的總體緩解率(ORR)及完全緩解率(CRR)分別為84.0%及40.0%,而R/R MZL的總體緩解率於兩例可評估患者達100.0%,表明突出的療效信號。研究目前在積極招募及觀察中。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account